Denny Jacob

1 week ago | in.marketscreener.com | Denny Jacob

Published on 27/05/2025 at 16:57, updated on 27/05/2025 at 16:58 By Denny Jacob BeiGene's Tevimbra gets a highly sought after recommendation. The oncology company said the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion of its treatment in combination with gemcitabine and cisplatin for adults with recurrent, not amenable to curative surgery or radiotherapy, or metastatic nasopharyngeal cancer.

2 weeks ago | wsj.com | Denny Jacob

Newly built homes have been getting smaller since the pandemic—a trend home builders have been leaning into to entice buyers and alleviate costsAs the housing market goes through the critical spring selling season, size matters. Buyers who are trying to purchase their first home but find themselves boxed out of their dream because of persistently high prices and mortgage rates, as well as low supply, are making certain concessions, just as builders are doing what it takes to close deals.

2 weeks ago | wsj.com | Chip Cutter |Denny Jacob

The company, which makes most of its money from government-related work, expects to trim 7% of its workforce; shares fall 15%Shares fell 15% in early trading Friday after Booz Allen executives told investors the firm is seeing a slowdown in some government spending and that it expected its business to be under pressure in the first half of the fiscal year. Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8Subscribe NowAlready a subscriber? Sign In

2 weeks ago | wsj.com | Denny Jacob

Booz Allen BAH 0.55%increase; green up pointing triangle Hamilton posted revenue growth that came in below expectations in its latest quarter while its guidance for the current fiscal year also underwhelmed, sending its stock lower before the bell. The consulting firm on Friday said it recorded net income of $193 million, or $1.52 a share, for the fourth quarter ended March 31, up from $128 million, or 98 cents a share, in the prior-year period. Copyright ©2025 Dow Jones & Company, Inc.

2 weeks ago | tradingview.com | Denny Jacob

Booz Allen Hamilton 4Q Revenue, FY26 Guidance DisappointBAHBooz Allen Hamilton posted revenue growth that came in below expectations in its latest quarter while its guidance for the current fiscal year also underwhelmed, sending its stock lower before the bell. The consulting firm on Friday said it recorded net income of $193 million, or $1.52 a share, for the fourth quarter ended March 31, up from $128 million, or 98 cents a share, in the prior-year period.